Boehringer Ingelheim collaborations for treatment of schizophrenia

Saniona and Boehringer Ingelheim GmbH (“Boehringer Ingelheim”) have two ongoing partnerships for the discovery and development of new small molecule therapeutics to restore brain network activity in patients with schizophrenia. By combining Saniona’s expertise in ion channels and related technology platforms with Boehringer Ingelheim’s expertise in research and clinical development and commercialization, we are well positioned to advance new treatment options for schizophrenia.

The first Schizophrenia collaboration with Boehringer Ingelheim was initiated in 2016 and Boehringer Ingelheim selected the first candidate for preclinical and clinical development in July 2018, triggering a milestone payment of €4 million to Saniona. The program is in the preclinical development phase in preparation for clinical studies.

Boehringer Ingelheim is responsible for the preclinical and clinical development and has global commercial rights. Saniona is eligible to receive up to €90 million in milestone payments and royalties on worldwide net sales of any resulting products under the collaboration. As of December 2019, Saniona has received a total of €9 million under the collaboration excluding earned income under the research collaboration. 

The second research and development collaboration with Boehringer Ingelheim was initiated in March 2020. The objective is to identify new treatment options for schizophrenia, by exploring a novel undisclosed CNS ion channel target using Saniona’s ion channel drug discovery platform. Boehringer Ingelheim has exclusive worldwide rights to research, develop, manufacture and commercialize therapeutics identified through the collaboration. In addition, Saniona will receive research funding during the joint research period. During the first year of the collaboration, Saniona expects to receive research funding of around € 0.45 million.

Boehringer Ingelheim, founded in 1885, is one of the world’s 20 leading pharmaceutical companies. The focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.